基于免疫组织化学的分子分类与传统风险分层对子宫内膜癌复发和生存结果的影响
Yoshimasa Kawarai1, Akira Mitsuhashi2, Shuhei Noda3
1Department of Obstetrics and Gynecology, Dokkyo Medical University, 880 Kitakobayashi, Shimotsugagun, Mibu, Tochigi, 321-0293, Japan.
International journal of clinical oncology
|November 25, 2025
概括
一种新的免疫组织化学 (IHC) 方法有效地对子宫内膜癌 (EC) 风险进行了分类,确定p53-异常 (p53abn) 是一个不良的预后标志物. 这种具有成本效益的方法有助于个性化治疗,当遗传检测无法获得时.
科学领域:
- 在瘤学瘤学.
- 分子病理学分子病理学
- 癌症基因组学 癌症基因组学
背景情况:
- 传统的子宫内膜癌 (EC) 风险分层缺乏分子洞察力,影响预后和治疗.
- 对子宫内膜癌的积极分子风险分类器 (ProMisE) 使用昂贵的下一代测序用于DNA聚合酶epsilon (POLE) 突变.
- 需要在欧洲共同体进行可访问的,基于分子的风险评估.
研究的目的:
- 评估一种新的算法,将免疫组织化学 (IHC) 与常规因子结合起来,用于子宫内膜癌风险分层.
- 评估基于IHC的分子分析在EC的预后价值.
- 确定IHC是否可以为EG风险分类提供基因测试的成本效益替代方案.
主要方法:
- 对237名接受手术的I-III阶段EC患者的回顾性分析.
- 没有IHC的低风险患者的分类;因不匹配修复缺陷 (MMRd),p53异常 (p53abn) 和非特异分子谱 (NSMP) 而被IHC分类的中等和高风险患者.
- 使用卡普兰-梅尔曲线和考克斯回归的L1CAM表达和生存分析的评估.
主要成果:
- 对233例病例的分析,随访时间中位数为63个月,显示87名低风险患者的复发率很低.
- 中级/高风险组包括42名MMRd,16名p53abn和88名NSMP患者.
- 五年无病生存率为98.8% (低风险),94.7% (NSMP),80.6% (MMRd) 和59.8% (p53abn);p53abn独立预测了复发 (HR 10.1) 和死亡率 (HR 25.6).
结论:
- 将常规风险因素与p53的IHC和不匹配修复 (MMR) 结合起来,为子宫内膜癌提供了一个具有成本效益的预后工具.
- 这种基于IHC的方法可以实现准确的风险分层和个性化治疗决策.
- 这种方法即使在像ProMisE这样的先进基因测试无法获得时也是有价值的.
更多相关视频
05:16Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
3.7K
07:46Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
1.8K
相关概念视频
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...